Pacira BioSciences (PCRX) FY2013 results: revenue $86 million, up 118.9% on the year
Pacira BioSciences, Inc. (PCRX) reported revenue of $86 million for fiscal 2013, the year ended 31 December 2013, up 118.9% on the year before. Net income was -$64 million, and diluted earnings per share $-1.93. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2014.
Revenue
$86 million
+118.9% on the year
FY2009FY2013
Operating margin
-62.3%
-126.1% a year earlier
FY2009FY2013
Net income
-$64 million
FY2009FY2013
Diluted EPS
-$1.93
FY2009FY2013
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Revenue
85.6
39.1
15.7
+118.9%
Cost of revenue
54.8
32.1
16.7
+70.4%
Gross profit
30.8
6.9
-1.1
+343.2%
Gross margin
36.0%
17.8%
-6.7%
Research and development
21.6
9.9
14.9
+117.0%
Selling, general and administrative
62.5
46.3
20.2
+35.0%
Operating income
-53.3
-49.3
-39.1
Operating margin
-62.3%
-126.1%
-249.2%
Interest expense
7.3
1.8
4.8
+301.4%
Pre-tax income
-64.4
-52.3
-43.3
Income tax
-0.4
0.0
0.0
Net income
-63.9
-52.3
-43.3
Net margin
-74.7%
-133.8%
-276.2%
Diluted EPS
-$1.93
-$1.72
-$2.64
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Operating cash flow
-43.8
-70.1
-31.0
Capital expenditure
12.2
18.3
6.2
-33.3%
Free cash flow
-56.0
-88.4
-37.2
Free cash flow margin
-65.5%
-226.1%
-236.9%
Depreciation and amortisation
5.7
5.6
4.3
+1.8%
Share-based compensation
11.5
4.8
2.5
+141.1%
Diluted shares, weighted
33m
30m
16m
+9.4%
Shares outstanding at period end
34m
33m
25m
+3.1%
Balance sheet
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Shareholders' equity
41.2
65.9
48.3
-37.4%
Debt
99.0
25.2
25.6
+292.8%
Other liabilities
29.6
21.0
39.6
+40.9%
Total liabilities and equity
170
112
113
+51.6%
Fixed assets
48.2
39.1
25.1
+23.2%
Goodwill
10.3
8.3
0.0
+24.5%
Intangible assets
1.2
3.2
5.3
-63.9%
Investments
59.6
30.9
30.0
+92.9%
Cash and equivalents
12.5
12.5
46.2
0.0%
Receivables
14.6
4.4
2.1
+235.2%
Inventory
15.6
12.1
1.2
+28.8%
Other assets
7.9
1.6
3.6
+401.9%
Total assets
170
112
113
+51.6%
10-K for the year ended 31 December 2013, filed 25 February 2014: the filing.